Study proves the effectiveness of Parkinson’s drug apomorphine

News

Author: Parkinson's Life editorsPublished: 11 May 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Results from the 12-week TOLEDO study – which tested the effectiveness of APO-go®/MOVAPO® (apomorphine) on Parkinson’s patients whose symptoms could not be controlled with standard therapies – showed that patients treated with the infusion had a significantly greater improvement in ‘off’ time, compared with those taking the placebo.

The reduction in ‘off’ time was achieved without an increase in dyskinesias and was reflected in the patients’ own assessment of the overall treatment effect.

The results were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, US, last month.

Professor Katzenschlager, lead investigator of the TOLEDO study, said: “TOLEDO provides the high-level evidence we needed for the efficacy and tolerability of apomorphine infusion in patients who are still experiencing debilitating treatment response fluctuations despite receiving optimised treatment, and confirms the clinical experience of those who have used apomorphine infusion for many years.”

Go Back

Share this story

Comments


Related articles


Episodes

“A space where people with Parkinson’s can speak their minds”

The Parkinson’s Life podcast wins Global Content Award

READ MORE
Boston Scientific deep brain stimulation

sponsored article

Advances

Global collaboration in deep brain stimulation

Four Parkinson’s experts share their hopes for the future of DBS

READ MORE
Scientists working in a lab

Special reports

Prostate drug could “change the lives of people with Parkinson’s”

The drug could slow down and stop Parkinson’s progression

READ MORE